Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasonermin - Genentech/Boehringer Ingelheim

Drug Profile

Tasonermin - Genentech/Boehringer Ingelheim

Alternative Names: Beromun; FK 516; TNF alpha - Genentech/Boehringer Ingelheim; TNF alpha-1a - Genentech/Boehringer Ingelheim; Tumour necrosis factor alpha - Genentech/Boehringer Ingelheim

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Amarillo Biosciences; Asahi Kasei; Genentech; Hayashibara
  • Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Tumour necrosis factors
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sarcoma
  • Preregistration Submission Withdrawal Cancer

Most Recent Events

  • 11 Jun 2015 Launched for Sarcoma in Latvia, Lithuania, Luxembourg, Slovakia, Croatia, Estonia, Austria, Finland, France, Hungary, Malta, Romania and Slovenia (IV) before June 2015
  • 04 Oct 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 20 Jan 2000 Mochida has withdrawn the NDA for TNFα in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top